GlaxoSmithKline, Novartis and Iomi Land Avian Flu Vaccine Contracts
by H.S. Ayoub
BioHealth Investor.com
The Department of Health and Human Services (DHHS) has awarded GlaxoSmithKline (GSK), Novartis Vaccines and Diagnostics (NVS) and Iomi (IOMI) all a total of $133 million in funding for the development of H5N1 Avain Flu vaccines.
GSK's contract will total $63 million over 5 years, while Novartis will receive $55 million over the same period.
Iomi was awarded just $14 million over 15 months for the completion of phase I trials of its skin patch designed to stimulate the immune system when used along with vaccines. The company can be awarded a further $114 million if the study shows positive results.
Each of the three companies are expected, under the terms of the contracts, to be able to provide 150 million doses of the vaccines within 6 months of the start of an Avain Flu pandemic attack.
Shares of GSK and Novartis both gained just a little over 1% on Wednesday, while Iomi jumped more than 15% to end trading at $5.88, with an intra-day high of $6.85.
RELATED READING:
- Project BioShield Has Given Biotechs Little Motivation to Protect Americans
____________________
BioHealth Investor.com
The Department of Health and Human Services (DHHS) has awarded GlaxoSmithKline (GSK), Novartis Vaccines and Diagnostics (NVS) and Iomi (IOMI) all a total of $133 million in funding for the development of H5N1 Avain Flu vaccines.
GSK's contract will total $63 million over 5 years, while Novartis will receive $55 million over the same period.
Iomi was awarded just $14 million over 15 months for the completion of phase I trials of its skin patch designed to stimulate the immune system when used along with vaccines. The company can be awarded a further $114 million if the study shows positive results.
Each of the three companies are expected, under the terms of the contracts, to be able to provide 150 million doses of the vaccines within 6 months of the start of an Avain Flu pandemic attack.
Shares of GSK and Novartis both gained just a little over 1% on Wednesday, while Iomi jumped more than 15% to end trading at $5.88, with an intra-day high of $6.85.
RELATED READING:
- Project BioShield Has Given Biotechs Little Motivation to Protect Americans
____________________
posted by Nico at
8:42 PM
1 Comments:
Novartis has put together a brilliant marketing campaign to increase sales. The idea; to get kids on Ritalin through school psychologists and psychiatrists was pure genius. They came up with disorders; attention-deficit-disorder, mood-disorder, obsessive compulsive-disorder, anxiety-disorder, conversion-disorder, panic-disorder, phobic-disorder and on and on. All you have to do is hyphen disorder onto an emotion or a disability, whip up a drug to handle it and presto, the money pours in.
And now the other drug companies are copying Novartis.
The best thing is that these new clients as they get older will need more and more Ritalin, as it is basically an amphetamine and most will be on some form of it for the rest of their lives; thus insuring growth. And now I see that they are working on getting babies on it. Wow! Will the brilliance ever cease?
The outrageous allegations that Ritalin is a starter drug that creates addicts that then do street crime are just spurious charges done by people who are jealous of the money that Novartis and their investors make.
Post a Comment
Subscribe to Post Comments [Atom]
<< Home